UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2015
TRACON Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-36818 | | 34-2037594 |
(State or other jurisdiction | | (Commission File Number) | | (IRS Employer Identification No.) |
of incorporation) | | | | |
8910 University Center Lane, Suite 700
San Diego, California | | 92122 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 550-0780
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 1, 2015, TRACON Pharmaceuticals, Inc. (TRACON) announced that Santen Pharmaceutical Co. Ltd. (Santen) filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration for the initiation of clinical studies for DE-122 in patients with wet age-related macular degeneration (AMD). DE-122 is the ophthalmic formulation of TRACON’s proprietary anti-endoglin antibody, TRC105. In March 2014, Santen licensed the global rights for the development of TRC105 in ophthalmology from TRACON. Under the terms of the licensing agreement, the IND filing for DE-122 triggered a $3 million milestone payment to TRACON.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRACON Pharmaceuticals, Inc. |
| |
Dated: July 6, 2015 | |
| By: | /s/ Charles P. Theuer, M.D., Ph.D. |
| | Charles P. Theuer, M.D., Ph.D. |
| | President and Chief Executive Officer |
3
